GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BioLargo Inc (OTCPK:BLGO) » Definitions » Net Current Asset Value

BioLargo (BioLargo) Net Current Asset Value : $0.02 (As of Dec. 2023)


View and export this data going back to 1991. Start your Free Trial

What is BioLargo Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

BioLargo's net current asset value per share for the quarter that ended in Dec. 2023 was $0.02.

The historical rank and industry rank for BioLargo's Net Current Asset Value or its related term are showing as below:

BLGO' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 8.4   Med: 19.49   Max: 21.22
Current: 17.63

During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of BioLargo was 21.22. The lowest was 8.40. And the median was 19.49.

BLGO's Price-to-Net-Current-Asset-Value is ranked worse than
83.78% of 931 companies
in the Chemicals industry
Industry Median: 5.1 vs BLGO: 17.63

BioLargo Net Current Asset Value Historical Data

The historical data trend for BioLargo's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLargo Net Current Asset Value Chart

BioLargo Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Current Asset Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.03 - 0.01 0.01 0.02

BioLargo Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.02 0.02 0.02 0.02

Competitive Comparison of BioLargo's Net Current Asset Value

For the Chemicals subindustry, BioLargo's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLargo's Price-to-Net-Current-Asset-Value Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, BioLargo's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where BioLargo's Price-to-Net-Current-Asset-Value falls into.



BioLargo Net Current Asset Value Calculation

BioLargo's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net Current Asset Value Per Share(A: Dec. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(6.362-4.003--2.642-0)/292.946
=0.02

BioLargo's Net Current Asset Value (NCAV) per share for the quarter that ended in Dec. 2023 is calculated as

Net Current Asset Value Per Share(Q: Dec. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(6.362-4.003--2.642-0)/292.946
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioLargo  (OTCPK:BLGO) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


BioLargo Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of BioLargo's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLargo (BioLargo) Business Description

Traded in Other Exchanges
N/A
Address
14921 Chestnut Street, Westminster, CA, USA, 92683
BioLargo Inc invents, develops, and commercializes platform technologies to solve challenging environmental problems like PFAS contamination, advanced water, and wastewater treatment, industrial odor, and VOC control, air quality control, and infection control. The company holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. BioLargo invents or acquires novel technologies and develops them to maturity through its operating subsidiaries. It monetizes through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation, and/or the sale of the IP. The firm's technologies are commercially available and are advancing as disrupters in their respective markets.
Executives
Linda Park director 14921 CHESTNUT STREET, WESTMINSTER CA 92683
Christina Elaine Bray director PO BOX 234, FREDERICK CO 80530
Jack B. Strommen director 7108 31ST AVENUE N., MINNEAPOLIS MN 55427
Roberts Kent Charles Ii director 1146 OXFORD ROAD, SAN MARINO CA 91108
John S. Runyan director 30001 HILLSIDE TERRACE, SAN JUAN CAPISTRANO CA 92675
Dennis E Marshall director 3500 W. GARRY AVENUE, SANTA ANA CA 92705
Dennis P Calvert director, 10 percent owner, officer: Chief Executive Officer 3500 GARRY AVE, SANTA ANA CA 92704
New Millennium Capital Partners, Llc 10 percent owner 16333 PHOEBE AVENUE, LA MIRADA CA 90638
Charles K Dargan officer: Chief Financial Officer 8055 W. MANCHESTER AVE., SUITE 405, PLAYA DEL REY CA 90293
Joseph L Provenzano director, officer: Corporate Secretary 3500 W. GARRY AVENUE, SANTA ANA CA 92704
Iowc Technologies, Inc. 10 percent owner 2603 MAIN STREET, SUITE 1155, IRVINE CA 92614
Kenneth Reay Code 10 percent owner 16150 HERON AVENUE, LA MIRADA CA 90638
Gary Adrian Cox director 3500 W. GARRY AVENUE, SANTA ANA CA 92705
Steven V Harrison director
Eduardo Ruiz director, 10 percent owner